Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595829 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of XL019 in Adults With Polycythemia Vera
A Phase 1 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00595829: Clinical Trial Phase 1 study, sponsored by Exelixis.
NCT00595829 is a Phase 1 study that was terminated before completion, run by Exelixis. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00595829, a Phase 1 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
Interventions
- DRUG XL019
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 1 |
Why NCT00595829 stopped before completion
NCT00595829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which XL019 is the first listed.
NCT00595829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00595829 about?
NCT00595829 is a clinical study titled "A Phase 1 Study of XL019 in Adults With Polycythemia Vera". The purpose of this study is to evaluate the safety and tolerability of the JAK2 inhibitor XL019 administered orally in adults with Polycythemia Vera.
What is the current status of trial NCT00595829?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2007-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00595829?
The interventions under investigation include: XL019 (DRUG).
Who is sponsoring clinical trial NCT00595829?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00595829's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia